Literature DB >> 2788424

Prevalence of scleroderma spectrum disorders in the general population of South Carolina.

H R Maricq1, M C Weinrich, J E Keil, E A Smith, F E Harper, A I Nussbaum, E C LeRoy, A R McGregor, F Diat, E J Rosal.   

Abstract

The prevalence of scleroderma spectrum disorders (including systemic sclerosis [SSc] meeting the American Rheumatism Association criteria and the less typical disorders meeting only our study criteria) was determined in a random sample of 6,998 subjects from the general population of South Carolina. The results suggest that the prevalence of these disorders may range from 67 to 265 per 100,000, which is 4.9 to 19.2 times higher than previously reported for definite SSc. The ratio of nondefinite cases to definite cases of SSc (those meeting American Rheumatism Association criteria) was 2.5. Most of the nondefinite cases were unrecognized prior to our study, which suggests the need for improved early diagnosis of scleroderma spectrum disorders. Brief histories of the 7 patients with scleroderma spectrum disorders whose cases formed the basis for our calculation of prevalence rates are included in this report.

Entities:  

Mesh:

Year:  1989        PMID: 2788424     DOI: 10.1002/anr.1780320809

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  26 in total

1.  Primary care assessment of capillaroscopy abnormalities in patients with Raynaud's phenomenon.

Authors:  Rebecca Overbury; Maureen A Murtaugh; Aryeh Fischer; Tracy M Frech
Journal:  Clin Rheumatol       Date:  2015-09-23       Impact factor: 2.980

Review 2.  Raynaud's phenomenon: its relevance to scleroderma.

Authors:  J J Belch
Journal:  Ann Rheum Dis       Date:  1991-11       Impact factor: 19.103

Review 3.  Recent advances in the treatment of systemic sclerosis.

Authors:  Vasiliki Kalliopi K Bournia; Panayiotis G Vlachoyiannopoulos; Carlo Selmi; Haralampos M Moutsopoulos; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2009-06       Impact factor: 8.667

4.  The prevalences of some rheumatic diseases in western Turkey: Havsa study.

Authors:  Necati Cakır; Ömer Nuri Pamuk; Emine Derviş; Neşe Imeryüz; Haşim Uslu; Ömer Benian; Edip Elelçi; Genco Erdem; Fatma Oğuz Sarvan; Mustafa Senocak
Journal:  Rheumatol Int       Date:  2011-01-13       Impact factor: 2.631

Review 5.  My approach to the treatment of scleroderma.

Authors:  Ami A Shah; Fredrick M Wigley
Journal:  Mayo Clin Proc       Date:  2013-04       Impact factor: 7.616

6.  Serum levels of leptin receptor in patients with systemic sclerosis.

Authors:  Yukimi Ohyoshi; Takamitsu Makino; Masatoshi Jinnin; Wakana Nakayama; Satoshi Fukushima; Yuji Inoue; Hironobu Ihn
Journal:  Intractable Rare Dis Res       Date:  2013-05

7.  Serum levels of soluble CD163 in patients with systemic sclerosis.

Authors:  Wakana Nakayama; Masatoshi Jinnin; Katsunari Makino; Ikko Kajihara; Takamitsu Makino; Satoshi Fukushima; Yuji Inoue; Hironobu Ihn
Journal:  Rheumatol Int       Date:  2010-12-01       Impact factor: 2.631

Review 8.  The primary care physician in the early diagnosis of systemic sclerosis: the cornerstone of recognition and hope.

Authors:  Lesley Ann Saketkoo; Jeanette H Magnus; Mittie K Doyle
Journal:  Am J Med Sci       Date:  2014-01       Impact factor: 2.378

9.  Analysis of human antitopoisomerase-I idiotypes.

Authors:  D Vazquez-Abad; V Pascual; M Zanetti; N F Rothfield
Journal:  J Clin Invest       Date:  1993-09       Impact factor: 14.808

10.  Epidemiological study of patients with systemic sclerosis in Tokyo.

Authors:  T Tamaki; S Mori; K Takehara
Journal:  Arch Dermatol Res       Date:  1991       Impact factor: 3.017

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.